Scientists say identification of two epigenetically different states in mouse model opens door to "entirely new world of ...

The typical treatment for estrogen receptor positive (ER+) breast cancer involves surgery and years of hormone therapy that ...

Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women. Treatment ...

Limited to estrogen receptor-positive breast cancer (ER+) the compound addresses many common concerns with existing treatment ...

Researchers have revolutionized cancer immunotherapy by developing a way to grow T cells in the lab that live longer and ...

Learn how early developmental patterns can influence your lifetime cancer risk and the type of cancer that may develop.

An approach using engineered small extracellular vesicles from NK cells to DR5 could be a promising strategy for solid tumors ...

“It is very rare for a compound to shrink tumors in mouse models of breast cancer, let alone completely eradicate those tumors with a single dose, so we are eager for ErSO-TFPy to advance for ...

Now, researchers reporting in ACS Central Science have created a novel treatment that eliminated small breast tumors and significantly shrank large tumors in mice in a single dose, without problematic ...

However, a new drug candidate could hold the potential to eliminate the need for such a grueling process, after a study in mice found that it wiped out a range of breast tumors in a single dose.

SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis, in human pancreatic tumors harboring a G12D mutation ...